BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures. Foresite Capital and Eshelman Ventures...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...Therapeutics Inc. via a $22.5 million series A round last July that was led by Eshelman Ventures...
BioCentury | Aug 18, 2016
Emerging Company Profile

Negative thinking for brain cancer

...collaborators: Columbia University Corporate partners: None Number of employees: 3 Funds raised: $22.5 million Investors: Eshelman Ventures...
BioCentury | Jul 18, 2016
Financial News

Sapience completes venture financing

...Scarsdale, N.Y. Business: Cancer Date completed: 2016-07-12 Type: Venture financing Raised: $22.5 million Investors: Eshelman Ventures...
BioCentury | Jul 13, 2016
Financial News

Cancer newco Sapience raises $22.5M

...Therapeutics Inc. (Scarsdale, N.Y.) raised $22.5 million in an untranched series A round led by Eshelman Ventures...
BioCentury | May 16, 2016
Financial News

G1 Therapeutics completes venture financing

...Investors: Cormorant Asset Management; AJU IB Investment; Cowen Private Investments; Franklin Templeton; Rock Springs Capital; Eshelman Ventures...
BioCentury | May 12, 2016
Financial News

G1 raises $47M in C round

...Private Investments, Franklin Templeton Investments and Rock Springs Capital also participated, as did existing investors Eshelman Ventures...
BioCentury | Apr 20, 2015
Financial News

Innocrin Pharmaceuticals completes venture financing

...Durham, N.C. Business: Cancer Date completed: 2015-04-14 Type: Venture financing Raised: $28 million Investors: Eshelman Ventures...
BioCentury | Feb 9, 2015
Financial News

G1 Therapeutics completes venture financing

...Triangle Park, N.C. Business: Cancer Date completed: 2015-02-05 Type: Venture financing Raised: $33 million Investors: Eshelman Ventures...
BioCentury | Feb 6, 2015
Financial News

G1 Therapeutics raises $33M in B round

...Triangle Park, N.C.) raised $33 million in a series B round led by new investors Eshelman Ventures...
Items per page:
1 - 10 of 10
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures. Foresite Capital and Eshelman Ventures...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

...Therapeutics Inc. via a $22.5 million series A round last July that was led by Eshelman Ventures...
BioCentury | Aug 18, 2016
Emerging Company Profile

Negative thinking for brain cancer

...collaborators: Columbia University Corporate partners: None Number of employees: 3 Funds raised: $22.5 million Investors: Eshelman Ventures...
BioCentury | Jul 18, 2016
Financial News

Sapience completes venture financing

...Scarsdale, N.Y. Business: Cancer Date completed: 2016-07-12 Type: Venture financing Raised: $22.5 million Investors: Eshelman Ventures...
BioCentury | Jul 13, 2016
Financial News

Cancer newco Sapience raises $22.5M

...Therapeutics Inc. (Scarsdale, N.Y.) raised $22.5 million in an untranched series A round led by Eshelman Ventures...
BioCentury | May 16, 2016
Financial News

G1 Therapeutics completes venture financing

...Investors: Cormorant Asset Management; AJU IB Investment; Cowen Private Investments; Franklin Templeton; Rock Springs Capital; Eshelman Ventures...
BioCentury | May 12, 2016
Financial News

G1 raises $47M in C round

...Private Investments, Franklin Templeton Investments and Rock Springs Capital also participated, as did existing investors Eshelman Ventures...
BioCentury | Apr 20, 2015
Financial News

Innocrin Pharmaceuticals completes venture financing

...Durham, N.C. Business: Cancer Date completed: 2015-04-14 Type: Venture financing Raised: $28 million Investors: Eshelman Ventures...
BioCentury | Feb 9, 2015
Financial News

G1 Therapeutics completes venture financing

...Triangle Park, N.C. Business: Cancer Date completed: 2015-02-05 Type: Venture financing Raised: $33 million Investors: Eshelman Ventures...
BioCentury | Feb 6, 2015
Financial News

G1 Therapeutics raises $33M in B round

...Triangle Park, N.C.) raised $33 million in a series B round led by new investors Eshelman Ventures...
Items per page:
1 - 10 of 10